The Danish medical device giant Coloplast has officially concluded its ten-month search for a permanent leader by appointing Gavin Wood, a veteran of the global healthcare industry, as its new Chief Executive Officer. Wood, who most recently served as the Company Group Chairman for Johnson & Johnson MedTech in the Europe, Middle East, and Africa (EMEA) region, is scheduled to assume his new responsibilities on May 1. This appointment marks the end of a transitional period for the Humlebæk-based company, which has been under the interim leadership of its Chairman, Lars Rasmussen, since May 2025. Wood’s arrival coincides with a pivotal moment for Coloplast as it navigates a shifting global landscape, particularly regarding its long-term strategy in the Chinese market and its ongoing expansion into diversified chronic care sectors.
The leadership vacancy was created following the departure of former CEO Kristian Villumsen, who left the manufacturer of ostomy, continence, urology, and wound care products nearly a year ago. At the time of Villumsen’s exit, the Coloplast Board of Directors framed the leadership change as a deliberate step to usher in a “new strategy period.” By selecting an executive with deep roots in one of the world’s largest healthcare conglomerates, Coloplast appears to be signaling an intention to bolster its operational scale and refine its commercial execution across its diverse portfolio of medical technologies.
A Strategic Appointment Following a Ten-Month Search
The selection of Gavin Wood follows an extensive international recruitment process intended to find a leader capable of balancing Coloplast’s heritage in specialized chronic care with the aggressive growth targets required by modern MedTech investors. Wood’s professional background is defined by a two-decade tenure at Johnson & Johnson, a period during which he ascended through various high-stakes leadership roles. His most recent position as EMEA Chairman for J&J MedTech involved overseeing a multibillion-dollar business unit with a workforce exceeding 7,000 employees. His remit covered critical healthcare sectors, including advanced surgery, orthopedics, cardiovascular health, and specialty solutions.
Prior to his regional chairmanship, Wood served as the Worldwide President of Ethicon’s wound closure and healing division, a role that aligns closely with Coloplast’s own wound care business. His experience is not limited to the American corporate environment; he also served as the Executive Vice President of Commercial at the Swedish firm Mölnlycke, a major competitor in the global wound care and surgical product markets. This blend of experience—ranging from the massive scale of a Fortune 50 company to the specialized focus of European MedTech leaders—is expected to provide Wood with the perspective necessary to lead Coloplast through its next phase of evolution. Wood, a Canadian national currently residing in Switzerland, will relocate to Denmark to take up the role, a move that underscores the company’s commitment to maintaining its strong Nordic identity while pursuing a global agenda.
The Transition Period: From Kristian Villumsen to Lars Rasmussen
The departure of Kristian Villumsen in May 2025 came at a time when Coloplast was beginning to evaluate its long-term trajectory. Villumsen’s tenure saw significant milestones, including the integration of major acquisitions and a steady focus on innovation in the ostomy and continence care spaces. However, the board’s decision to seek a new leader for the “new strategy period” suggested a desire for a different set of competencies to address emerging headwinds in international trade and healthcare reimbursement.
During the ten-month interim period, Lars Rasmussen, the current Chairman of the Board, stepped back into the operational fold as interim CEO. Rasmussen’s deep familiarity with the company—having served as its CEO from 2008 to 2018 before becoming Chairman—provided a sense of stability for shareholders and employees alike. Under his temporary stewardship, Coloplast continued to execute its existing plans while the search committee vetted candidates for the permanent role. Rasmussen will continue to lead the company through the end of April, ensuring a smooth handover of responsibilities to Wood on May 1.
Navigating the "New Strategy Period": Coloplast’s Evolving Mission
Coloplast’s origins as an ostomy specialist have expanded significantly over the decades. Today, the company operates across four primary business areas: Ostomy Care, Continence Care, Interventional Urology, and Wound & Skin Care. Each of these segments serves patients with chronic conditions, a market characterized by high loyalty and recurring revenue but also subject to intense regulatory scrutiny and pricing pressures.
The “new strategy period” referenced by the board likely involves a three-pronged approach: accelerating digital health integration, expanding the footprint in the United States, and re-evaluating the growth potential of emerging markets. In recent years, Coloplast has invested heavily in digital tools designed to help patients manage their conditions more effectively, such as apps that track stoma health or provide personalized advice for continence management. Wood’s experience at J&J, which has been a leader in integrating robotics and digital solutions into surgery, may prove invaluable as Coloplast seeks to monetize its digital offerings.
The China Headwind: Addressing Stagnant Growth in a Key Market
Perhaps the most significant challenge awaiting Wood is the recalibration of Coloplast’s strategy in China. For over a decade, China was viewed as the primary engine of growth for the company’s international operations. Coloplast invested heavily in local infrastructure, sales forces, and distribution networks within the country, betting on the rising middle class and an aging population to drive demand for premium medical supplies.
However, recent financial reports indicate a sharp reversal in this trend. During a capital markets day last year, Lars Rasmussen stated bluntly that China is “definitely not a growth platform anymore.” This sentiment was echoed in the company’s earnings release for the first quarter of the 2025-26 financial year, which highlighted “soft” ostomy sales. Falling revenues in China were cited as a primary factor, with the region being the only geographic area where chronic care sales saw a decline.
The slowdown in China is attributed to several factors common across the MedTech industry, including the implementation of Volume-Based Procurement (VBP) policies by the Chinese government. These policies aim to drive down the cost of medical devices by awarding large contracts to manufacturers who offer the lowest prices, often favoring local domestic producers over international firms. For a company like Coloplast, which positions its products as premium, high-quality solutions, the price-driven nature of VBP presents a significant hurdle to maintaining profit margins. Wood will need to determine whether to double down on local manufacturing in China to compete on cost or to pivot resources toward more lucrative or stable markets.
Portfolio Diversification and the Role of M&A
As the organic growth in traditional markets matures, Coloplast has increasingly looked toward mergers and acquisitions (M&A) to bolster its portfolio. The 2022 acquisition of Atos Medical, a leader in laryngectomy care, for approximately $2.5 billion represented a major step into a new chronic care segment. This move allowed Coloplast to diversify its revenue streams and leverage its existing global distribution network.
Industry analysts expect that under Wood’s leadership, Coloplast may continue to seek out bolt-on acquisitions that complement its existing strengths. Given Wood’s background in surgery and orthopedics at J&J, there is speculation that he might look for opportunities to expand Coloplast’s Interventional Urology or Wound Care segments, where the technological barriers to entry are higher and the competitive advantages are more defensible.
Market Outlook: Challenges and Opportunities for the Incoming CEO
The global MedTech industry is currently facing a complex set of macro-economic pressures, including inflationary costs in raw materials, logistics disruptions, and a tightening reimbursement environment in both Europe and the United States. Despite these challenges, the fundamental demand for Coloplast’s products remains robust due to the non-discretionary nature of chronic care.
Investors will be watching Wood’s first 100 days closely for signs of how he intends to improve operational efficiency. At J&J, Wood was part of an organization known for rigorous cost management and lean manufacturing. Applying these principles to Coloplast could help the company maintain its industry-leading EBIT (Earnings Before Interest and Taxes) margins, which have historically hovered around 30%.
Furthermore, the United States remains a critical frontier. While Coloplast has a strong presence in the U.S., it faces stiff competition from domestic players like Hollister and Convatec. Expanding market share in the U.S. hospital and home-care settings will likely be a top priority for Wood, as the U.S. market offers more favorable pricing dynamics compared to many European single-payer systems.
Conclusion: A New Chapter for a Danish MedTech Giant
The appointment of Gavin Wood marks the beginning of a new chapter for Coloplast. By bringing in an outsider with significant global experience, the board is demonstrating a willingness to challenge the status quo and adapt to a more volatile global economy. Wood’s deep understanding of the MedTech sector, combined with his experience managing large-scale operations across diverse geographies, makes him a formidable choice to lead the company through its next strategic cycle.
As Wood prepares to take the helm on May 1, the focus will remain on how he addresses the immediate concerns regarding the Chinese market while simultaneously laying the groundwork for long-term innovation. For the patients who rely on Coloplast’s products every day, the hope is that this new leadership will continue the company’s tradition of high-quality care while driving the technological advancements necessary for the future of chronic disease management. For shareholders, the expectation is a return to consistent growth and the successful execution of the “new strategy period” that has been nearly a year in the making.